表3. 慢性原发免疫性血小板减少症患者首剂利妥昔单抗治疗后不同随访截点的敏感度、特异度、阳性预测值和阳性预测值.
指标 | 首剂利妥昔单抗治疗后时间(d) |
|||||||||||
1 | 3 | 5 | 7 | 14 | 21 | 30 | 60 | 90 | 180 | 270 | 360 | |
敏感度 | 0.359 | 0.462 | 0.410 | 0.436 | 0.487 | 0.487 | 0.564 | 0.872 | 0.923 | 0.949 | 0.949 | 0.940 |
特异度 | 0.828 | 0.750 | 0.734 | 0.564 | 0.875 | 0.781 | 0.812 | 0.937 | 0.937 | 0.953 | 0.969 | 0.970 |
PPV(%) | 68.2 | 65.9 | 60.7 | 50.0 | 51.3 | 69.0 | 70.4 | 89.4 | 93.6 | 95.2 | 96.8 | 96.9 |
NPV(%) | 58.2 | 58.2 | 55.4 | 50.0 | 96.5 | 60.4 | 74.7 | 92.3 | 92.4 | 94.9 | 95.0 | 94.1 |
注:PPV:阳性预测值;NPV:阴性预测值。以血小板计数50×109/L为预测疗效的最佳界值